Radiopharmacy giant Syncor International has cut a new three-year agreement and two-year renewal option with Broadlane, a major provider of supply chain services to the healthcare industry. The agreement, which takes effect immediately, establishes
Radiopharmacy giant Syncor International has cut a new three-year agreement and two-year renewal option with Broadlane, a major provider of supply chain services to the healthcare industry. The agreement, which takes effect immediately, establishes Syncor as the distributor of radiopharmaceuticals, including FDG, to Broadlane’s 572 acute care hospitals and 2335 subacute healthcare facilities. In addition to the sole source agreement, Broadlane will also make available to its members Syncor’s PharmaSeed I-125 brachytherapy seeds.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.